Αρχική World News FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for Patients... World News FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for Patients with BRAF V600E-mutated mCRC Από Ogkologos - 24 Ιανουαρίου, 2025 836 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Immunoscore Classification Significantly Associates with Time to Recurrance In Asian Patients... 21 Νοεμβρίου, 2020 Cancer Survivors Face High Rates of Housing Insecurity 5 Φεβρουαρίου, 2022 FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma 7 Φεβρουαρίου, 2022 Online Dating During COVID-19 and Cancer: What to Know 11 Φεβρουαρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Granting a Marketing Authorisation for Capivasertib How Breast Cancer Risk Assessment Tools Work ESMO Highlights the Importance of a Strong EU Commitment Towards Robust... No Improvement in OS with Adding Palbociclib to Letrozole for the...